Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tuberculosis, Mycobacterium Infection Clear all
Completed No phase listed Observational

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Cabotegravir (CAB), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Not applicable Interventional Results available

An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment

NCT03266003
View directory record Official record
Conditions
Tuberculosis, Drug-resistant Tuberculosis, Adherence, Medication, Adherence, Patient
Interventions
Electronic DOT, In-person DOT
Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Brooklyn, New York • Jackson Heights, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers

NCT00992069
View directory record Official record
Conditions
Tuberculosis, HIV
Interventions
Efavirenz (EFV), TMC207
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
San Francisco, California • Baltimore, Maryland • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 3:06 AM EDT
Completed No phase listed Observational

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

NCT01587469
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
Cepheid
Industry
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

NCT03891901
View directory record Official record
Conditions
Tuberculosis
Interventions
Imatinib, Isoniazid, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

NCT04865536
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

NCT03510468
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tenofovir alafenamide, Rifapentine, Isoniazid (INH), Pyridoxine
Drug · Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Jul 23, 2026, 3:06 AM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 23, 2026, 3:06 AM EDT
Completed No phase listed Observational

Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance

NCT02534727
View directory record Official record
Conditions
Tuberculosis, Non-Tuberculosis Mycobacteria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Quality by Maintaining Accurate Problems in the EHR

NCT02596087
View directory record Official record
Conditions
Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease, Congestive Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, Sickle Cell Disease, Sleep Apnea, Smoking, Stroke, Tuberculosis
Interventions
Problem List Suggestion
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Camp Hill, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 23, 2026, 3:06 AM EDT
Completed No phase listed Observational

Latent Tuberculosis Infection in Cancer Patients

NCT00507754
View directory record Official record
Conditions
Advanced Cancer
Interventions
T-SPOT TB test
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

NCT04309656
View directory record Official record
Conditions
Multi-drug Resistant Tuberculosis
Interventions
Pretomanid
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

NCT07542847
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPC-167832, Itraconazole, Carbamazepine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

NCT00694629
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
rifampin, rifapentine
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 23, 2026, 3:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy

NCT00925249
View directory record Official record
Conditions
Rheumatoid Arthritis, Tuberculosis
Interventions
Not listed
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2009 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 4 Interventional Results available

Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis

NCT01960257
View directory record Official record
Conditions
Tuberculosis
Interventions
Digital Health Feedback System, SOC DOT
Device · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 23, 2026, 3:06 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Azacytidine During Anti-tuberculosis Therapy

NCT03941496
View directory record Official record
Conditions
Tuberculosis, Pulmonary
Interventions
Azacitidine Injection
Drug
Lead sponsor
Andrew Dinardo
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 23, 2026, 3:06 AM EDT
Not listed Not applicable Interventional

Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen

NCT00018083
View directory record Official record
Conditions
Tuberculosis, HIV Infections
Interventions
rifabutin, isoniazid, efavirenz
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

NCT01599897
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
ID93 + GLA-SE, ID93 alone
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123
View directory record Official record
Conditions
Tuberculosis, AIDS-related Complex
Interventions
Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 2Phase 3 Interventional

TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB

NCT00023348
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Rifabutin
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

NCT00023452
View directory record Official record
Conditions
Tuberculosis
Interventions
RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
2 Years and older
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Not applicable Interventional

Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents

NCT00233168
View directory record Official record
Conditions
Lung Diseases, Tuberculosis
Interventions
Adherence Program, Life Skills and Self-Esteem Training Program (Attention Control Arm)
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
13 Years to 18 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Jul 23, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

NCT02508376
View directory record Official record
Conditions
Tuberculosis
Interventions
AP10-602, GLA-SE, ID93
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 23, 2026, 3:06 AM EDT